Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, if he will undertake a review of the decision not to procure Evusheld for people vulnerable to Covid-19 this winter.

The decision not to procure Evusheld at this time for prevention through emergency routes is based on independent clinical advice by the multi-agency RAPID C-19 and a national expert policy working group. The decision is based on a range of evidence, including clinical trial data, in vitro analysis and emerging observational studies. RAPID C-19 monitors activity in clinical trials for emerging evidence and where treatments are proven to be clinically effective to enable access for National Health Service patients. The Chief Medical Officer for England is content that the correct process for providing clinical advice has been followed and it has now been referred to the National Institute for Health and Care Excellence for further evaluation.